Vitamin E-bisphosphonate conjugates: A new therapeutic approach targeting pathological bone loss associated with osteoporosis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1050694

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Approximately 2 million Australians have osteoporosis, a disease which increases the risk of fracture and whose monetary and social costs are large and growing. The objective of this proposal is to exploit the osteotropic properties of novel compounds of vitamin E (VE) derivatives (BPVE) conjugated to bisphosphonates (BP), which will have anti-oxidant, anti-osteolytic and bone anabolic properties, and will be taken up selectively in the skeleton for the treatment of osteoporosis.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $471,984.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antioxidant therapy | bisphosphonates | bone formation | bone loss | osteoclastogenesis | osteolysis | osteoporosis | vitamin E

Related Links